Basic aspects of Catechol-O-methyltransferase and the clinical applications of its inhibitors
Edited by- Erkki Nissinen, Orion Corporation, Espoo, Finland
Volume 95 of International Review of Neurobiology focuses on Catechol-O-methyltransferase inhibition, and its clinical application in relation to Parkinsons disease. Chapters cover COMT gene and proteins, L-dopa treatment in Parkinsons disease, the latest research on COMT inhibitors and their clinical applications, as well as future prospects for their use.
Audience
Neuroscientists, neurologists, psychologists, gerontologists
Included in series
International Review of Neurobiology
International Review of Neurobiology
Hardbound, 336 Pages
Published: December 2010
Imprint: Academic Press
ISBN: 978-0-12-381326-8
Contents
- Introductory remarks: Catechol-O-methyltransferase inhibition: an innovative approach to enhance L-dopa therapy in Parkinsons disease with dual enzyme inhibition
- The catechol-O-methyltransferase gene, its regulation and polymorphisms Elizabeth M. Tunbridge
- Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture?
- Catechol-O-methyltransferase enzyme: Cofactor S-adenosyl-L-methionine and related mechanisms Thomas Müller
- Biochemistry and pharmacology of catechol-O-methyltrasferase inhibitors
- The Chemistry of Catechol-O-methyltransferase Inhibitors David A. Learmonth, László E. Kiss and Patrício Soares-da-Silva
- Toxicology and safety of COMT inhibitors
- Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of the L-dopa treatment Concepció Marin, J.A. Obeso
- Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinsons disease
- Catechol-O-methyltransferase and pain
Erkki Nissinen
Timo T. Myöhänen & Pekka T. Männistö
Erkki Nissinen and Pekka T. Männistö
Kristiina Haasio
Seppo Kaakkola
Oleg Kambur & Pekka T. Männistö
